ILLUMINATE Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
==Objective== | ==Objective== | ||
Raising HDL levels by a combination of torcetrapib, a CETP inhibitor, and atorvastatin, an HGM-CoA reductase inhibitor. | Raising HDL levels by a combination of torcetrapib, a CETP inhibitor, and atorvastatin, an HGM-CoA reductase inhibitor. | ||
== | |||
==Timeline== | |||
===Start Date=== | ===Start Date=== | ||
August 23, 2004 | August 23, 2004 | ||
| Line 14: | Line 15: | ||
==Methods== | ==Methods== | ||
* Phase III trial | * Phase III trial | ||
* | * Prospective, randomized, multicenter, double-blind clinical trial that recuited 15,067 patients. | ||
* Inclusion criteria: Patients aged 45-75 years who have a history of cardiovascular disease 30 days to 5 years before screening; patients who have type 2 diabetes mellitus that meet criteria of the American Diabetes Association or receive anti-diabetic agents, even without previous cardiovascular disease. | * Inclusion criteria: Patients aged 45-75 years who have a history of cardiovascular disease 30 days to 5 years before screening; patients who have type 2 diabetes mellitus that meet criteria of the American Diabetes Association or receive anti-diabetic agents, even without previous cardiovascular disease. | ||
* Exclusion criteria: Unstable medical condition, life expectancy less than 5 years, LDL-C levels < 100 mg/dL, those not receiving anti-lipidemic medications, if LDL-C target level not achieved at termination of run-in period, and those who have cardiovascular event during run-in period or uncontrolled hypertension: SBP>140 mmHg or DBP>90 mmHg, | * Exclusion criteria: Unstable medical condition, life expectancy less than 5 years, LDL-C levels < 100 mg/dL, those not receiving anti-lipidemic medications, if LDL-C target level not achieved at termination of run-in period, and those who have cardiovascular event during run-in period or uncontrolled hypertension: SBP>140 mmHg or DBP>90 mmHg, | ||
* Run-in period: 4-10 weeks | * Run-in period: 4-10 weeks | ||
*Cardiovascular disease was defined as myocardial infarction, stroke, acute coronary syndrome, unstable angina, peripheral vascular disease, and cardiac revascularization. | * Cardiovascular disease was defined as myocardial infarction, stroke, acute coronary syndrome, unstable angina, peripheral vascular disease, and cardiac revascularization. | ||
* Two arms of the study: Atorvastatin alone or atorvastatin plus torcetrapib 60 mg. Dosage of atorvastatin was determined while achieving of target LDL-C levels during run-in period and can be changed during the study period according to LDL-C levels. | * Two arms of the study: Atorvastatin alone or atorvastatin plus torcetrapib 60 mg. Dosage of atorvastatin was determined while achieving of target LDL-C levels during run-in period and can be changed during the study period according to LDL-C levels. | ||
* Primary Outcome was defined as the time to first “cardiovascular event”. | * Primary Outcome was defined as the time to first “cardiovascular event”. | ||
* | * “Cardiovascular event” defined as death from coronary artery disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. Procedure-related deaths and events were excluded. | ||
* Secondary outcome: time to the first occurrence of a primary outcome. Time to death regardless of the etiology, change from baseline LDL and HDL levels. | * Secondary outcome: time to the first occurrence of a primary outcome. Time to death regardless of the etiology, change from baseline LDL and HDL levels. | ||
* Outcomes based on 1,3,6,9, and 12 months scheduled visits. | * Outcomes based on 1,3,6,9, and 12 months scheduled visits. | ||
==Results== | ==Results== | ||
* Median follow-up: 550 days | |||
* Follow-up completion: 99.7% of patients | |||
* Early discontinuation: 11% in atorvastatin group and 13.4% in torcetrapib group. | |||
* One year follow-up showed increase of HDL (72.1%), a decrease of LDL (24.9%), and a decrease of 9% of triglycerides among patients on torcetrapib vs. minimal change in lipid profile in atorvastatin group (p<0.001). | |||
* After 3 months follow-up, there was a small, but significant, change in CRP levels (p=0.01) | |||
* After 12 months follow-up, blood pressure decrease was 0.9% in atorvastatin group vs. 5.4 mmHg in torcetrapib group (p<0.001). Torcetrapib group also have a 0.08 mmol/L decrease in potassium, a 1.39 mmol/L increase in sodium, and a 2.28 mmol/L increase in bicarbonate vs. an increase in all 3 among the atorvastatin group with electrolyte values increasing 0.06 mmol/L, 0.78 mmol/L, and 1.93 mmol/L, respectively (p<0.001).. | |||
* In contrast, estimated glomerular filtration rate (eGFR) increased 0.8 ml/min/1.73m2 in torcetrapib group, but decreased 0.3 ml/min/1.73m2 in the atorvastatin group (p<0.001) | |||
* QT interval changes after 12 months were 3.3 msec and 0.3 msec in torcetrapib and atorvastatin groups, respectively (p<0.001) | |||
* Measurements of aldosterone showed that after 3 months, there was a significant increase in aldosterone measurements in the torcetrapib group among 85th, 90th, and 95th percentile values. | |||
==Study Outcomes== | ==Study Outcomes== | ||
Revision as of 12:01, 18 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
ILLUMINATE Trial On the Web |
|
American Roentgen Ray Society Images of ILLUMINATE Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
Raising HDL levels by a combination of torcetrapib, a CETP inhibitor, and atorvastatin, an HGM-CoA reductase inhibitor.
Timeline
Start Date
August 23, 2004
End Date
Premature Termination on December 2, 2006. Data collection continued till July 15, 2007.
Methods
- Phase III trial
- Prospective, randomized, multicenter, double-blind clinical trial that recuited 15,067 patients.
- Inclusion criteria: Patients aged 45-75 years who have a history of cardiovascular disease 30 days to 5 years before screening; patients who have type 2 diabetes mellitus that meet criteria of the American Diabetes Association or receive anti-diabetic agents, even without previous cardiovascular disease.
- Exclusion criteria: Unstable medical condition, life expectancy less than 5 years, LDL-C levels < 100 mg/dL, those not receiving anti-lipidemic medications, if LDL-C target level not achieved at termination of run-in period, and those who have cardiovascular event during run-in period or uncontrolled hypertension: SBP>140 mmHg or DBP>90 mmHg,
- Run-in period: 4-10 weeks
- Cardiovascular disease was defined as myocardial infarction, stroke, acute coronary syndrome, unstable angina, peripheral vascular disease, and cardiac revascularization.
- Two arms of the study: Atorvastatin alone or atorvastatin plus torcetrapib 60 mg. Dosage of atorvastatin was determined while achieving of target LDL-C levels during run-in period and can be changed during the study period according to LDL-C levels.
- Primary Outcome was defined as the time to first “cardiovascular event”.
- “Cardiovascular event” defined as death from coronary artery disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. Procedure-related deaths and events were excluded.
- Secondary outcome: time to the first occurrence of a primary outcome. Time to death regardless of the etiology, change from baseline LDL and HDL levels.
- Outcomes based on 1,3,6,9, and 12 months scheduled visits.
Results
- Median follow-up: 550 days
- Follow-up completion: 99.7% of patients
- Early discontinuation: 11% in atorvastatin group and 13.4% in torcetrapib group.
- One year follow-up showed increase of HDL (72.1%), a decrease of LDL (24.9%), and a decrease of 9% of triglycerides among patients on torcetrapib vs. minimal change in lipid profile in atorvastatin group (p<0.001).
- After 3 months follow-up, there was a small, but significant, change in CRP levels (p=0.01)
- After 12 months follow-up, blood pressure decrease was 0.9% in atorvastatin group vs. 5.4 mmHg in torcetrapib group (p<0.001). Torcetrapib group also have a 0.08 mmol/L decrease in potassium, a 1.39 mmol/L increase in sodium, and a 2.28 mmol/L increase in bicarbonate vs. an increase in all 3 among the atorvastatin group with electrolyte values increasing 0.06 mmol/L, 0.78 mmol/L, and 1.93 mmol/L, respectively (p<0.001)..
- In contrast, estimated glomerular filtration rate (eGFR) increased 0.8 ml/min/1.73m2 in torcetrapib group, but decreased 0.3 ml/min/1.73m2 in the atorvastatin group (p<0.001)
- QT interval changes after 12 months were 3.3 msec and 0.3 msec in torcetrapib and atorvastatin groups, respectively (p<0.001)
- Measurements of aldosterone showed that after 3 months, there was a significant increase in aldosterone measurements in the torcetrapib group among 85th, 90th, and 95th percentile values.